<?xml version="1.0" encoding="UTF-8"?>
<p>The availability of a licensed vaccine poses different challenges to current dengue control programs since its gradual introduction is not expected to cover all susceptible and at-risk populations or even provide complete immunity in target groups. In each of these populations there are several questions that need to be addressed regarding the clinical spectrum and transmission risks where the vaccine or any other control innovation may provide a potential benefit [
 <xref rid="pntd.0006748.ref020" ref-type="bibr">20</xref>].
</p>
